Risks of duloxetine for stress incontinence outweigh benefits, say researchersBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6103 (Published 15 November 2016) Cite this as: BMJ 2016;355:i6103
- Barbara Kermode-Scott
- Vancouver Island
The antidepressant duloxetine should not be used to treat stress urinary incontinence in women because the harms outweigh the benefits, authors of a new analysis have said.
Although duloxetine reduced the symptoms of stress urinary incontinence and improved women’s quality of life, the harms related to suicidality and violence were 4 to 5 times more common with duloxetine than with a placebo, a meta analysis using patient level data by researchers from the Nordic Cochrane Centre showed.1
The researchers from Rigshospitalet in Copenhagen made their comments after conducting a meta-analysis using clinical study reports submitted to the European Medicines Agency for regulatory approval of duloxetine for stress urinary incontinence in women. They first gained access to clinical study …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.